58 RANDOMIZED, OPEN-LABEL, 12-WEEK COMPARISON OF CONTROLLED-RELEASE INTERFERON ALPHA2B +RIBAVRIN VS. PEGYLATED-INTERFERON ALPHA2B +RIBAVRIN IN TREATMENT-NAIVE GENOTYPE1 HEPATITIS C: 4 WEEK RESULTS FROM 480STUDY (PANEL A)

Autor:	B. Vladimirov, W.A. Long, D. Nikolovska, A. Rigney, Iskren Kotzev, F.A. Caruntu, I.G. Diaconescu, M. Voiculescu, K. Tchernev, Zahary Krastev
Rok vydání:	2010
Předmět:	Therapy naive Hepatology Pegylated interferon business.industry Interferon medicine Hepatitis C Pharmacology Open label medicine.disease business Controlled release medicine.drug
Zdroj:	Journal of Hepatology. 52:S27
ISSN:	0168-8278
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::5226ba4686efcf4fbbdaa611fc362176 https://doi.org/10.1016/s0168-8278(10)60060-8 Zobrazit plný text záznamu Full Text from ScienceDirect